Search Results
121 items found for "Addex Therapeutics"
- Noval insights and therapeutic strategies for tumor-induced kidney pathologies
< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases
< GPCR News < GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and
- Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers
< GPCR News < GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 date, many small-molecule CXCR2 antagonists have entered clinical trials, showing favorable safety and therapeutic
- Clinical, pathophysiologic, genetic and therapeutic progress in Primary Bilateral Macronodular Adrenal Hyperplasia
< GPCR News < GPCRs in Oncology and Immunology Clinical, pathophysiologic, genetic and therapeutic progress
- Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer
GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic specific siRNAs inhibits the growth of cisplatin-refractory ovarian cancer xenografts, demonstrating the therapeutic
- Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases
Oncology and Immunology Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic
- Principles of Pharmacology in Drug Discovery II
essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic November 7th: Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) wide repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.
- Ep 122 with Dr. Nicolas Gilles
He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic
- Ep 81 with Dr. Christel Menet
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.
- Ep 60 with Dr. Josephine (Pina) Cardarelli
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic
- Ep 95 with Chris Langmead
collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation
- Ep 79 with Dr. Graeme Milligan
Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics
- The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for therapeutic Despite its therapeutic potential, the insufficient understanding regarding of the receptor's structure and antibody recognition mechanism has impeded the progress of effective therapeutic development.
- Ep 107 with Dr. Roger Sunahara
bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic
- From odor to oncology: non-canonical odorant receptors in cancer
These findings shed light on the potential of non-canonical odorant receptors as therapeutic targets these chemoreceptors and various types of cancer, potentially paving the way for innovative odor-based therapeutics Ultimately, this review discusses the potential development of novel therapeutic strategies targeting
- GPCR Retreat 2023 - Part II
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)
- Ep 58 with Dr. Juan José Fung
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.
- Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
cancer (CRC) remains a major global cause of cancer-related mortality, lacking effective biomarkers and therapeutic Revealing the critical pathogenic factors of CRC and the underlying mechanisms would offer potential therapeutic proteins in CRC, identifying Regulator of G protein signaling 16 (RGS16) as a prospective diagnostic and therapeutic
- Principles of Pharmacology in Drug Discovery II
essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Variable. Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit.
- Ep 63 with Dr. Khaled Abdelrahman
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Ep 37 with Dr. Samuel Hoare
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Olfactory Receptors and Tumorigenesis: Implications for Diagnosis and Targeted Therapy
The potential for precise tumor diagnosis and targeted therapy through therapeutic targeting of olfactory Tang, Ye Tian, Chun-Xia Zhang, Guo-Tai Wang Tags G Protein-coupled receptors , Olfactory receptors , Therapeutic
- A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Ep 92 with Dr. Stephane Angers
He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics
- Ep 109 with Dr. Katarina Nemec
I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically
- Ep 84 with Rosie Dawaliby
In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases